Previous 10 | Next 10 |
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047 ǂ ). Dr. Moshe Mittelman’s presentation was sel...
2023-11-06 20:30:18 ET FibroGen, Inc. (FGEN) Q3 2023 Earnings Conference Call Nov 06, 2023, 05:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Thane Wettig - Chief Executive Officer Juan Graham - Chief Financial Offic...
2023-11-06 16:07:23 ET More on FibroGen FibroGen Q3 2023 Earnings Preview FibroGen names Thane Wettig as permanent CEO Seeking Alpha’s Quant Rating on FibroGen Historical earnings data for FibroGen Financial information for FibroGen For...
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision Promise SM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
FibroGen Inc (FGEN) is expected to report $-0.68 for Q3 2023
NEW YORK, NY / ACCESSWIRE / October 27, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fibrogen, Inc. ("Fibrogen" or "the Company") (NASDAQ:FGEN). Investors who purchased Fibrogen securities prior to December 1, 2018, and continue to ho...
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to fur...
2023-10-06 06:36:14 ET More on FibroGen FibroGen, Inc. (FGEN) Q2 2023 Earnings Call Transcript FibroGen, Inc. 2023 Q2 - Results - Earnings Call Presentation Biggest stock movers today: Outlook Therapeutics, Ambarella, HPQ, Box and more FibroGen stock tumbles ...
2023-08-30 13:16:02 ET Gainers: NanoVibronix ( NAOV ) +127% . iCoreConnect ( ICCT ) +49% . Aravive ( ARAV ) +35% . AEON Biopharma ( AEON ) +33% . Alarum Technologies ( ALAR ) +25% . Greenland Technologies Holding Corporation ...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...